Abstract
This retrospective observational analysis of health claims data compares the safety, effectiveness, and cost of biosimilar filgrastim and filgrastim.
Publication types
-
Letter
-
Observational Study
MeSH terms
-
Biosimilar Pharmaceuticals / administration & dosage*
-
Biosimilar Pharmaceuticals / economics
-
Chemoprevention / economics
-
Chemoprevention / methods
-
Chemoprevention / statistics & numerical data
-
Chemotherapy-Induced Febrile Neutropenia / economics
-
Chemotherapy-Induced Febrile Neutropenia / epidemiology
-
Chemotherapy-Induced Febrile Neutropenia / prevention & control*
-
Drug Administration Schedule
-
Drug Costs
-
Early Medical Intervention / economics
-
Early Medical Intervention / methods
-
Early Medical Intervention / standards
-
Female
-
Filgrastim / economics
-
Filgrastim / therapeutic use
-
Humans
-
Incidence
-
Intercellular Signaling Peptides and Proteins / administration & dosage*
-
Intercellular Signaling Peptides and Proteins / economics
-
Male
-
Middle Aged
-
Neoplasms / drug therapy*
-
Neoplasms / economics
-
Neoplasms / epidemiology
-
Palliative Care / economics
-
Palliative Care / methods*
-
Palliative Care / standards
-
Retrospective Studies
-
Treatment Outcome
-
United States / epidemiology
Substances
-
Biosimilar Pharmaceuticals
-
Intercellular Signaling Peptides and Proteins
-
Filgrastim